1 domain / 2 areas / 1 specialization
Subversive Capital
Data updated
Subversive Capital is a New York-based investment firm that operates across venture investing, public markets, activism, whistleblower financing, and ETFs. Public filings and the firm’s site describe it as active in early- and late-stage investments, with a focus on companies that operate in highly regulated or category-defining sectors.
In the psychedelic ecosystem, Subversive is relevant because it has participated in atai Life Sciences financing rounds, including atai’s Series D in 2021. Its public positioning and board-level involvement with atai suggest a broader interest in regulated mental health and psychedelic-adjacent opportunities.
Investor Context
Venture CapitalInvestment Context
This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage signals include Seed, Series A/B, and Growth / Late Stage. Public focus areas include Drug Development.
Subversive Capital appears to be a strategy-driven investor with a preference for businesses operating in regulated, high-conviction sectors rather than a narrow sector-only mandate. Public materials describe the firm as investing from venture through public markets and SPAC-related transactions, and its involvement with atai Life Sciences ties it to the psychedelic and mental health innovation landscape. The firm’s public address is in New York City.
Investor Type
Venture Capital Fund
Geographic Scope
Global
Psychedelic Focus
Psychedelic-Adjacent Focus
Engagement
Active
Investment Stage Focus
Investment Focus Areas
Quick Facts
- Founded
- 2013
- HQ
- 217 Centre Street, Suite 122, New York, NY 10013, United States
- Website
- Visit